Literature DB >> 19917762

In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.

Catharine C Bulik1, Henry Christensen, David P Nicolau.   

Abstract

We describe the activity of a novel cephalosporin, CXA-101 (FR26 4205), against a panel of highly resistant Pseudomonas aeruginosa isolates collected from U.S. hospitals. CXA-101 demonstrated increased potency against this population of resistant isolates, with activity that is 4- to 10-fold higher than that of comparator agents in each phenotypic category. The addition of tazobactam did not improve its activity. CXA-101 appears to be a promising addition to the category of antipseudomonal beta-lactams.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19917762      PMCID： PMC2798502          DOI： 10.1128/AAC.00912-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa.

Authors:  Shinobu Takeda; Yoshikazu Ishii; Kazuo Hatano; Kazuhiro Tateda; Keizo Yamaguchi
Journal:  Int J Antimicrob Agents       Date:  2007-07-17       Impact factor: 5.283

2.  Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa.

Authors:  Christian G Giske; James Ge; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2009-05-27       Impact factor: 5.790

3.  Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.

Authors:  Ayako Toda; Hidenori Ohki; Toshio Yamanaka; Kenji Murano; Shinya Okuda; Kohji Kawabata; Kazuo Hatano; Keiji Matsuda; Keiji Misumi; Kenji Itoh; Kenji Satoh; Satoshi Inoue
Journal:  Bioorg Med Chem Lett       Date:  2008-07-24       Impact factor: 2.823

4.  In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.

Authors:  Kathryn J Eagye; Joseph L Kuti; Christina A Sutherland; Henry Christensen; David P Nicolau
Journal:  Clin Ther       Date:  2009-11       Impact factor: 3.393

5.  Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

Authors:  David M Livermore; Shazad Mushtaq; Yigong Ge; Marina Warner
Journal:  Int J Antimicrob Agents       Date:  2009-05-09       Impact factor: 5.283

Review 6.  The current state of multidrug-resistant gram-negative bacilli in North America.

Authors:  Anthony M Nicasio; Joseph L Kuti; David P Nicolau
Journal:  Pharmacotherapy       Date:  2008-02       Impact factor: 4.705

7.  Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.

Authors:  Mariana Castanheira; Ronald N Jones; David M Livermore
Journal:  Diagn Microbiol Infect Dis       Date:  2009-02-26       Impact factor: 2.803

8.  Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002.

Authors:  Robert K Flamm; Mellany K Weaver; Clyde Thornsberry; Mark E Jones; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

9.  Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.

Authors:  Ronald N Jones; Jeffrey T Kirby; Paul R Rhomberg
Journal:  Diagn Microbiol Infect Dis       Date:  2008-03-10       Impact factor: 2.803

10.  Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.

Authors:  José-Manuel Rodríguez-Martínez; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191
View more
  20 in total

1.  In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Authors:  Catharine C Bulik; Pamela R Tessier; Rebecca A Keel; Christina A Sutherland; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

Authors:  A Walkty; J A Karlowsky; H Adam; M Baxter; P Lagacé-Wiens; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

3.  Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.

Authors:  Mordechai Grupper; Christina Sutherland; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 4.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

5.  Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Authors:  Gabriel Cabot; Sebastian Bruchmann; Xavier Mulet; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Susanne Haussler; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

6.  Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.

Authors:  Bartolomé Moyá; Alejandro Beceiro; Gabriel Cabot; Carlos Juan; Laura Zamorano; Sebastián Alberti; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

Review 7.  Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Authors:  George G Zhanel; Phillip Chung; Heather Adam; Sheryl Zelenitsky; Andrew Denisuik; Frank Schweizer; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Andrew Walkty; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

8.  Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.

Authors:  Bartolomé Moyá; Laura Zamorano; Carlos Juan; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

9.  Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Authors:  A J Lepak; A Reda; K Marchillo; J Van Hecker; W A Craig; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

10.  Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.

Authors:  Deanna J Buehrle; Ryan K Shields; Liang Chen; Binghua Hao; Ellen G Press; Ammar Alkrouk; Brian A Potoski; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.